A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC).
Fatima Karzai(National Institutes of Health), Jung‐Min Lee(National Cancer Institute), William L. Dahut(National Cancer Institute), Daniel C. Edelman(National Institutes of Health), Lisa M. Cordes(National Institutes of Health Clinical Center), Jane B. Trepel(National Institutes of Health), Amy Hankin(National Institutes of Health), Ravi A. Madan(National Cancer Institute), Marijo Bilušić(National Institutes of Health), Marc R. Theoret(United States Food and Drug Administration), James L. Gulley(National Cancer Institute), Farhad Fakhrejahani(National Institutes of Health), Anna Couvillon(National Institutes of Health), Nicole Houston(Johns Hopkins University), Helen Owens(National Institutes of Health), Paul S. Meltzer(National Cancer Institute)
Cited by 20
Related Papers
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
|Nature Medicine|2001|2.7k
Targeting the dynamic HSP90 complex in cancer
|Nature reviews. Cancer|2010|1.5k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
|Nature Medicine|2015|711